NCT05203068View on ClinicalTrials.gov

Specificity Trial of the Recombinant Tuberculosis Allergen in BCG Vaccinated Healthy Volunteers

NACompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

November 24, 2021

Primary Completion Date

January 18, 2022

Study Completion Date

January 26, 2022

Conditions
Tuberculosis
Interventions
DIAGNOSTIC_TEST

Recombinant tuberculosis allergen (RTA)

Single intradermal application of 0.2 µg/0.1 mL RTA (CFP10-ESAT6) in the middle of the forearm

Trial Locations (1)

Unknown

National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Moscow

All Listed Sponsors
lead

National Medical Research Center of Phthisiopulmonology and Infectious Diseases

OTHER_GOV

NCT05203068 - Specificity Trial of the Recombinant Tuberculosis Allergen in BCG Vaccinated Healthy Volunteers | Biotech Hunter | Biotech Hunter